Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY AD CHRONOS: Dupilumab + TCS in Moderate-to-Severe Atopic Dermatitis
NCT02260986Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2014
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in atopic dermatitis (AD) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Proportion of patients with Investigator's Global Assessment score of 0 or 1 and >=2 point reduction at 52 weeks. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02260986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260986.